CVS Health Corp. · Healthcare
Survives a correction-sized 3-point cut to analyst growth.
At a 2.2% margin the price requires 2.1% 3y revenue CAGR against 4.2% consensus, a cushion of +2.3pt versus a 0pt correction cut. Cushion clears the cut, so the price survives the correction on consensus estimates. Managed-care recovery story; not an AI name.
Breaks if: medical cost trend reverses the margin recovery from 1.6% toward 2.7%. We re-check this against analyst estimates every evening.
10 years, at a 2% margin analysts expect
+3.5%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
22 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 214% of reported profit arrived as operating cash, so the analysts' margin stands.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 9, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price at the price sits at the very bottom of 22 published models (0th percentile by count), fully endorsing only the HSBC target at $103 and rejecting a wall of 15 bull cases up to $126, meaning the market is paying for current guidance but refuses to credit any further upside.
Whether CVS can convert its raised 2026 guidance into sustained margin expansion and higher cash flow, rather than using the gains to absorb elevated medical costs — and the wired data can only track unit volumes to see if the top-line growth holds, not the pricing or cost trends that would settle the margin question.
What the price refuses to pay for, and the full reconstruction, on the CVS quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names